Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma

Journal of Hepatology

Volumn 53, Issue 1, 2010, Pages 126-131

  Hsu, Chih Hung ^a,b   Shen, Ying Chun ^a   Lin, Zhong Zhe ^a,b   Chen, Pei Jer ^a   Shao, Yu Yun ^a   Ding, Yea Hui ^a   Hsu, Chiun ^a,b   Cheng, Ann Lii ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Hepatocellular carcinoma; Metronomic chemotherapy; Sorafenib; Tegafur uracil

Indexed keywords

ALPHA FETOPROTEIN; AMINOTRANSFERASE; CREATININE; HEPATITIS B SURFACE ANTIGEN; SORAFENIB; TRIACYLGLYCEROL LIPASE; UFT; UFUR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE; TEGAFUR; URACIL;

ADULT; ADVANCED CANCER; AGE DISTRIBUTION; AGED; ANEMIA; ANOREXIA; ARTICLE; BLEEDING; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CYTOLOGY; DIARRHEA; DISEASE CLASSIFICATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EDEMA; EPIGASTRIC PAIN; ESOPHAGUS VARICES; FATIGUE; FEMALE; FEVER; GASTRIC ULCER BLEEDING; HAIR LOSS; HAND FOOT SYNDROME; HOARSENESS; HUMAN; HYPERBILIRUBINEMIA; HYPERMAGNESEMIA; HYPERTENSION; HYPOCALCEMIA; HYPONATREMIA; INFECTION; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER FUNCTION; LIVER HISTOLOGY; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALAISE; MALE; METRONOMIC CHEMOTHERAPY; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; OPEN STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; PROTEINURIA; SCORING SYSTEM; SEX DIFFERENCE; SIDE EFFECT; TASTE DISORDER; THERAPY DELAY; THROMBOCYTOPENIA; TREATMENT RESPONSE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VOMITING; ANALOGS AND DERIVATIVES; CARCINOMA, HEPATOCELLULAR; CHEMICALLY INDUCED; DISEASE FREE SURVIVAL; DRUG ERUPTIONS; KAPLAN MEIER METHOD; LIVER NEOPLASMS; MIDDLE AGED; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANOREXIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; DIARRHEA; DISEASE-FREE SURVIVAL; DRUG ERUPTIONS; FATIGUE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; PYRIDINES; TEGAFUR; URACIL;

EID: 77953124105     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2010.01.035     Document Type: Article

References (31)

1. Cheng A.L., Kang Y.K., Chen Z., Tsao C.J., Qin S., Kim J.S., et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10 (2009) 25-34
2. Hsu C., Shen Y.C., Cheng C.C., Hu F.C., and Cheng A.L. Geographic difference in survival outcome for advanced hepatocellular carcinoma: implications on future clinical trial design. Contemp Clin Trials 31 (2010) 55-61
3. Llovet J.M., Burroughs A., and Bruix J. Hepatocellular carcinoma. Lancet 362 (2003) 1907-1917
4. Wilhelm S.M., Carter C., Tang L., Wilkie D., McNabola A., Rong H., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64 (2004) 7099-7109
5. Llovet J.M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.F., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359 (2008) 378-390
6. Abou-Alfa G.K., Schwartz L., Ricci S., Amadori D., Santoro A., Figer A., et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24 (2006) 4293-4300
7. Furuse J., Ishii H., Nakachi K., Suzuki E., Shimizu S., and Nakajima K. Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci 99 (2008) 159-165
8. Yau T., Chan P., Ng K.K., Chok S.H., Cheung T.T., Fan S.T., et al. Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response. Cancer 115 (2009) 428-436
9. Pinter M., Sieghart W., Graziadei I., Vogel W., Maieron A., Königsberg R., et al. Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. Oncologist 14 (2009) 70-76
10. Wörns M.A., Weinmann A., Pfingst K., Schulte-Sasse C., Messow C.M., Schulze-Bergkamen H., et al. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. J Clin Gastroenterol 43 (2009) 489-495
11. Kerbel R.S., and Kamen B.A. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4 (2004) 423-436
12. Shaked Y., Emmenegger U., Man S., Cervi D., Bertolini F., Ben-David Y., et al. Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. Blood 106 (2005) 3058-3061
13. Klement G., Baruchel S., Rak J., Man S., Clark K., Hicklin D.J., et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105 (2000) R15-24
14. Colleoni M., Orlando L., Sanna G., Rocca A., Maisonneuve P., Peruzzotti G., et al. Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. Ann Oncol 17 (2006) 232-238
15. Dellapasqua S., Bertolini F., Bagnardi V., Campagnoli E., Scarano E., Torrisi R., et al. Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol 26 (2008) 4899-4905
16. Kohne C.H., and Peters G.J. UFT: mechanism of drug action. Oncology (Huntingt) 14 (2000) 13-18
17. Schmoll H.J. Dihydropyrimidine dehydrogenase inhibition as a strategy for the oral administration of 5-fluorouracil: utility in the treatment of advanced colorectal cancer. Anticancer Drugs 14 (2003) 695-702
18. Tokyo Liver Cancer Chemotherapy Study Group. Phase II study of co-administration of uracil and tegafur (UFT) in hepatocellular carcinoma. Japan J Clin Oncol 1985;15:559-62.
19. Ishikawa T., Ichida T., Sugitani S., Tsuboi Y., Genda T., Sugahara S., et al. Improved survival with oral administration of enteric-coated tegafur/uracil for advanced stage IV-A hepatocellular carcinoma. J Gastroenterol Hepatol 16 (2001) 452-459
20. Yonekura K., Basaki Y., Chikahisa L., Okabe S., Hashimoto A., Miyadera K., et al. UFT and its metabolites inhibit the angiogenesis induced by murine renal cell carcinoma, as determined by a dorsal air sac assay in mice. Clin Cancer Res 5 (1999) 2185-2191
21. Basaki Y., Chikahisa L., Aoyagi K., Miyadera K., Yonekura K., Hashimoto A., et al. Gamma-hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor. Angiogenesis 4 (2001) 163-173
22. Munoz R., Man S., Shaked Y., Lee C.R., Wong J., Francia G., et al. Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy. Cancer Res 66 (2006) 3386-3391
23. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (2000) 205-216
24. Kato H., Ichinose Y., Ohta M., Hata E., Tsubota N., Tada H., et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Eng J Med 350 (2004) 1713-1721
25. Makuch R., and Simon R. Sample size requirements for evaluating a conservative therapy. Cancer Treat Rep 62 (1978) 1037-1040
26. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 1998;28:751-5.
27. Maraveyas A., Lam T., Hetherington J.W., and Greenman J. Can a rational design for metronomic chemotherapy dosing be devised?. Br J Cancer 92 (2005) 1588-1590
28. Bertolini F., Shaked Y., Mancuso P., and Kerbel R.S. The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat Rev Cancer 6 (2006) 835-845
29. Bertolini F., Mancuso P., Shaked Y., and Kerbel R.S. Molecular and cellular biomarkers for angiogenesis in clinical oncology. Drug Discov Today 12 (2007) 806-812
30. Collette S., Bonnetain F., Paoletti X., Doffoel M., Bouché O., Raoul J.L., et al. Prognosis of advanced hepatocellular carcinoma: comparison of three staging systems in two French clinical trials. Ann Oncol 19 (2008) 1117-1126
31. Hsu C.H., Yang T.S., Hsu C., Toh H.C., Epstein R.J., Hsiao L.T., et al. Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma. Br J Cancer 102 (2010) 981-986